DIA/FDA Oligonucleotide-Based Therapeutics Conference

Early Bird Rates Expire in

DAYS

HOURS

MINUTES

SECONDS

Send Email 1.888.257.6457

Highlights & Features

What is happening at FDA/DIA Oligonucleotide-Based Therapeutics Conference

Need Approval in Order to Attend?

Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Three Track Meeting!

Track 1: Clinical:

There are more than a dozen oligonucleotide based products approved for therapeutic use and nearly 100 currently in clinical testing. Track 1 will explore the lessons learned and the ongoing challenges to clinical use of oligos.

Track 2: Nonclinical:

The nonclinical track will focus on development and safety assessments of oligonucleotide-based therapeutics.

Track 3: CMC:

This track provides an interactive forum for innovators and regulators to present and discuss cutting edge topics in oligonucleotide chemistry, manufacturing, and controls (CMC). The track emphasizes topics that are emerging and will require ongoing collaboration with global regulators. Attendees will take away a deeper understanding of key developments, along with insight into current challenges and successful strategies for navigating this complex area.

Have an account?